BMO Capital Markets Analysts Begin Coverage on Bristol Myers Squibb (BMY)
Equities researchers at BMO Capital Markets began coverage on shares of Bristol Myers Squibb (NYSE: BMY) in a report issued on Friday. The firm set an “outperform” rating and a $39.00 price target on the stock.
Shares of Bristol Myers Squibb traded down 0.30% during mid-day trading on Friday, hitting $32.623. Bristol Myers Squibb has a 52 week low of $25.69 and a 52 week high of $35.44. The company has a market cap of $55.103 billion and a P/E ratio of 14.68.
Bristol Myers Squibb last announced its earnings results on Thursday, April 26th. The company reported $0.64 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.64. The company’s revenue for the quarter was up 4.8% on a year-over-year basis. On average, analysts predict that Bristol Myers Squibb will post $0.41 earnings per share next quarter.
Separately, analysts at Zacks reiterated a “neutral” rating on shares of Bristol Myers Squibb in a research note to investors on Friday, April 27th. They now have a $35.00 price target on the stock.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis.